Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Considerations for Long-Acting Injectable PrEP

Listen as Jason Schafer, PharmD, MPH, shares key considerations for using long-acting injectable cabotegravir for PrEP, including management of missed dosing, stopping PrEP, and screening for HIV while receiving PrEP.
person default
Jason Schafer, PharmD, MPH
Released: March 21, 2022

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).

Listen as he gives his perspectives on:

  • The FDA approval of long-acting cabotegravir for PrEP
  • Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy
  • Considerations for long-acting cabotegravir as PrEP
    • Dosing and administration
    • Managing missed doses
    • Discontinuation
    • Delays in HIV diagnoses found in the HPTN 083 study in men
  • CDC recommendations for HIV screening while receiving PrEP

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

Jason Schafer, PharmD, MPH

Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Jason Schafer, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Merck and ViiV.

Program Medium

This program has been made available online.

Related Content

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this podcast from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: February 1, 2023

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

Dr Kenric Ware discusses considerations for ongoing PrEP candidacy and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 20, 2023

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this commentary from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings